Innoviva, Inc. (INVA) — closed signal from March 2, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 31, 2026.
Predicted vs. what happened
What happened
Reached 26% of the predicted growth at its peak, without hitting the target.
The thesis — published March 2, 2026
Management laid out a clear three-part growth plan and announced a $125 million stock buyback, which can prop the share price if it dips. An analyst raised their price target and kept a positive rating, keeping attention on the stock. Because trading can be thin, buy in stages so you don't get hurt by sudden swings.
Primary drivers
- $125M buyback can limit how far shares fall
- Analyst target hike keeps investor interest active
- Royalties plus new infectious-disease push strengthen growth story
- Recent overselling could lead to a quick rebound when pressure eases
How it played out
INVA: the target was not reached
Lyra published INVA at $22.93 on 2026-03-02 for a short-term window through 2026-05-31. The thesis expected 25% growth to $28.66. It pointed to a $125 million stock buyback, an analyst target hike, royalties plus a new infectious-disease push, and the chance that recent overselling could lead to a quick rebound.
Inside the window, INVA rose to a peak of $24.45 on 2026-04-20, a 6.6% gain. It stayed below the target and never reached $28.66. The stock ended the window at $21.42. The thesis partially played out on direction at the peak, but it missed the expected move.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.